ALARIS EQUITY PARTNERS ANNOUNCES $100 MILLION BOUGHT DEAL OFFERING OF TRUST UNITS, US$95 MILLION INVESTMENT INTO A NEW PARTNER, DISTRIBUTION INCREASE AND AMENDMENT TO CREDIT FACILITY

Alaris Equity Partners announced a C$100 million bought-deal unit offering at C$22.40 per unit, with a C$15 million over-allotment option, alongside a US$95 million investment in healthcare clinical-review provider Nexus Enterprises. The Nexus investment is expected to generate US$9.75 million of initial annualized preferred distributions, a 13% pre-tax yield on preferred capital, and be accretive to run-rate cash flow pro forma for the financing. Alaris also raised its quarterly distribution 2.6% to C$0.39 per unit and expanded its senior credit facility to US$500 million from US$450 million, while temporarily relaxing its leverage covenant to 3.25x from 3.00x through year-end.

Analysis

The financing structure should cap AD.UN near the bought-deal price through closing, creating a tactical entry window only if the post-deal discount exceeds the value of the incremental cash flow. The key underwriting question is not the stated preferred yield but whether Nexus' gross-profit-linked reset can sustain the upper end of its collar; a healthcare dispute-resolution business can appear low-capex while carrying concentrated payer, provider, or regulatory exposure. The common-equity stub adds upside but should receive little near-term valuation credit until realization terms and the customer concentration profile are disclosed.

Temporarily relaxing leverage headroom while issuing equity indicates Alaris is preserving acquisition capacity rather than simply de-risking. That is constructive if deployment continues at double-digit contractual yields, but it also raises the sensitivity of distributable cash flow to any partner-level distribution interruption: the covenant steps back down in Q1 2027, leaving limited time to demonstrate that new cash earnings offset incremental funded debt. CAD/USD is a second-order risk because the new cash distributions are USD-denominated while unitholder distributions and reporting are CAD-based; CAD weakness is an earnings tailwind, but reversal would dilute apparent accretion.

Consensus may overvalue the distribution increase as confirmation of durable coverage. The more informative catalysts are the next two quarterly disclosures: pro forma run-rate cash flow, actual debt drawn after closing, Nexus revenue/gross-profit performance, and the portfolio's deferred-distribution balance. CM and NA earn underwriting fees but have no meaningful earnings sensitivity; this is not a bank trade.

Key Decisions for Investors

• Watch AD.UN for a post-closing entry rather than buying ahead of September 28: initiate a 6-12 month long only if units trade at least 3-5% below the offering price or if management quantifies pro forma cash-flow accretion sufficient to preserve distribution coverage. Upside is yield/multiple normalization; downside is an underwritten deal price becoming a new valuation anchor.
• Use a 1-3 month event-driven long in AD.UN only after the prospectus discloses dilution, use of proceeds, and any material Nexus customer or regulatory concentration. Falsify the trade if pro forma funded-debt-to-contracted-EBITDA remains near the temporary 3.25x ceiling or if projected payout coverage weakens below the stated target range.
• For existing AD.UN exposure, hedge part of the incremental USD cash-flow exposure through a 6-month USD/CAD hedge if CAD appreciation becomes likely; a roughly 8-10% CAD move can materially alter translated distribution income even if Nexus operates to plan.
• Do not add CM or NA on this news. Revisit only if subsequent Canadian capital-markets issuance indicates a broader pipeline recovery; a single bought deal is immaterial to bank earnings and should not change positioning.